Moloney Securities Asset Management LLC Cuts Holdings in Solventum Co. (NYSE:SOLV)

Moloney Securities Asset Management LLC lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 13.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,561 shares of the company’s stock after selling 722 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Solventum were worth $301,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in SOLV. Trian Fund Management L.P. grew its position in Solventum by 32.9% during the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares during the last quarter. State Street Corp grew its holdings in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after purchasing an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum in the 3rd quarter worth $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Solventum by 0.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock worth $73,469,000 after purchasing an additional 3,745 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler lifted their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Mizuho began coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $68.29.

Solventum Stock Performance

NYSE SOLV opened at $74.29 on Tuesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The stock has a 50 day simple moving average of $70.40 and a two-hundred day simple moving average of $68.09.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.